<?xml version="1.0" encoding="UTF-8"?>
<jcr:root xmlns:jcr="http://www.jcp.org/jcr/1.0" xmlns:nt="http://www.jcp.org/jcr/nt/1.0" xmlns:mix="http://www.jcp.org/jcr/mix/1.0" xmlns:cq="http://www.day.com/jcr/cq/1.0" xmlns:sling="http://sling.apache.org/jcr/sling/1.0"
    jcr:primaryType="cq:Page">
    <jcr:content
        cq:lastModified="{Date}2024-02-08T16:34:14.050Z"
        cq:lastModifiedBy="msm-service"
        cq:lastRolledout="{Date}2024-02-08T16:34:14.053Z"
        cq:lastRolledoutBy="msm-service"
        cq:template="/conf/menarini-berlinchemie/settings/wcm/templates/menarini---details-news"
        jcr:isCheckedOut="{Boolean}true"
        jcr:mixinTypes="[cq:LiveRelationship,mix:versionable]"
        jcr:primaryType="cq:PageContent"
        jcr:title="Menarini Ricerche Announces SEL24/MEN1703 Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial"
        jcr:uuid="ca5f4d1e-f6f1-41eb-a3d9-02ed6e5abed1"
        sling:resourceType="menarinimaster/components/page"
        dnnNewsIdentifier="8a1c191b-1720-40aa-88de-c68d8076ed34-2280">
        <root
            cq:lastRolledout="{Date}2024-02-08T16:34:12.853Z"
            cq:lastRolledoutBy="msm-service"
            jcr:mixinTypes="[cq:LiveRelationship]"
            jcr:primaryType="nt:unstructured"
            sling:resourceType="menarinimaster/components/container"
            layout="responsiveGrid">
            <container
                cq:lastRolledout="{Date}2024-02-08T16:34:12.936Z"
                cq:lastRolledoutBy="msm-service"
                jcr:mixinTypes="[cq:LiveRelationship]"
                jcr:primaryType="nt:unstructured"
                sling:resourceType="menarinimaster/components/container"
                layout="responsiveGrid">
                <internalheader
                    cq:lastRolledout="{Date}2024-02-08T16:34:12.990Z"
                    cq:lastRolledoutBy="msm-service"
                    jcr:mixinTypes="[cq:LiveRelationship]"
                    jcr:primaryType="nt:unstructured"
                    jcr:title="News &amp; Medien"
                    sling:resourceType="menarinimaster/components/internalheader"
                    altValueFromDAM="{Boolean}false"
                    imageFromPageImage="{Boolean}false"
                    titleFromPage="{Boolean}false"/>
                <section
                    cq:lastRolledout="{Date}2024-02-08T16:34:12.996Z"
                    cq:lastRolledoutBy="msm-service"
                    jcr:lastModified="{Date}2024-02-08T16:34:12.992Z"
                    jcr:lastModifiedBy="a.messori@adiacent.com"
                    jcr:mixinTypes="[cq:LiveRelationship]"
                    jcr:primaryType="nt:unstructured"
                    sling:resourceType="menarinimaster/components/section">
                    <wrapper
                        cq:lastRolledout="{Date}2024-02-08T16:34:13.020Z"
                        cq:lastRolledoutBy="msm-service"
                        jcr:lastModified="{Date}2024-02-08T16:34:13.016Z"
                        jcr:lastModifiedBy="a.messori@adiacent.com"
                        jcr:mixinTypes="[cq:LiveRelationship]"
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/wrapper">
                        <breadcrumb
                            cq:lastRolledout="{Date}2024-02-08T16:34:13.045Z"
                            cq:lastRolledoutBy="msm-service"
                            jcr:mixinTypes="[cq:LiveRelationship]"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/breadcrumb"/>
                    </wrapper>
                </section>
                <container
                    cq:lastRolledout="{Date}2024-02-08T16:34:13.098Z"
                    cq:lastRolledoutBy="msm-service"
                    jcr:mixinTypes="[cq:LiveRelationship]"
                    jcr:primaryType="nt:unstructured"
                    sling:resourceType="menarinimaster/components/container"
                    layout="responsiveGrid">
                    <internalmenu
                        cq:lastRolledout="{Date}2024-02-08T16:34:13.144Z"
                        cq:lastRolledoutBy="msm-service"
                        jcr:mixinTypes="[cq:LiveRelationship]"
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/internalmenu"
                        navigationRoot="/content/menarini-berlinchemie/en/News-Medien"
                        structureStart="{Long}0">
                        <cq:responsive
                            cq:lastRolledout="{Date}2024-02-08T16:34:13.246Z"
                            cq:lastRolledoutBy="msm-service"
                            jcr:mixinTypes="[cq:LiveRelationship]"
                            jcr:primaryType="nt:unstructured">
                            <default
                                cq:lastRolledout="{Date}2024-02-08T16:34:13.354Z"
                                cq:lastRolledoutBy="msm-service"
                                jcr:mixinTypes="[cq:LiveRelationship]"
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="3"/>
                            <tablet
                                cq:lastRolledout="{Date}2024-02-08T16:34:13.360Z"
                                cq:lastRolledoutBy="msm-service"
                                jcr:mixinTypes="[cq:LiveRelationship]"
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="4"/>
                            <phone
                                cq:lastRolledout="{Date}2024-02-08T16:34:13.365Z"
                                cq:lastRolledoutBy="msm-service"
                                jcr:mixinTypes="[cq:LiveRelationship]"
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="12"/>
                        </cq:responsive>
                    </internalmenu>
                    <container
                        cq:lastRolledout="{Date}2024-02-08T16:34:13.512Z"
                        cq:lastRolledoutBy="msm-service"
                        cq:styleIds="[1684742346871]"
                        jcr:mixinTypes="[cq:LiveRelationship]"
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/container"
                        layout="responsiveGrid">
                        <news_data
                            cq:lastRolledout="{Date}2024-02-08T16:34:13.642Z"
                            cq:lastRolledoutBy="msm-service"
                            jcr:mixinTypes="[cq:LiveRelationship]"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/news_data"
                            newsDate="{Date}2020-12-01T10:07:00.000Z">
                            <cq:responsive
                                cq:lastRolledout="{Date}2024-02-08T16:34:13.668Z"
                                cq:lastRolledoutBy="msm-service"
                                jcr:mixinTypes="[cq:LiveRelationship]"
                                jcr:primaryType="nt:unstructured">
                                <default
                                    cq:lastRolledout="{Date}2024-02-08T16:34:13.700Z"
                                    cq:lastRolledoutBy="msm-service"
                                    jcr:mixinTypes="[cq:LiveRelationship]"
                                    jcr:primaryType="nt:unstructured"
                                    offset="0"
                                    width="9"/>
                            </cq:responsive>
                        </news_data>
                        <title
                            cq:lastRolledout="{Date}2024-02-08T16:34:13.708Z"
                            cq:lastRolledoutBy="msm-service"
                            cq:styleIds="[1653552493699]"
                            jcr:lastModified="{Date}2024-02-08T16:34:13.704Z"
                            jcr:lastModifiedBy="d.mariotti@adiacent.com"
                            jcr:mixinTypes="[cq:LiveRelationship]"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/title"
                            linkTarget="_self"
                            type="h2"/>
                        <image
                            cq:lastRolledout="{Date}2024-02-08T16:34:13.719Z"
                            cq:lastRolledoutBy="msm-service"
                            jcr:lastModified="{Date}2024-02-08T16:34:13.712Z"
                            jcr:lastModifiedBy="Importer"
                            jcr:mixinTypes="[cq:LiveRelationship]"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/image"
                            displayPopupTitle="true"
                            fileReference="/content/dam/menarini-berlinchemie/assets/news/img-diamond_thumbnail.jpg"
                            imageFromPageImage="{Boolean}false"
                            isDecorative="true"
                            linkTarget="_self"
                            titleValueFromDAM="false">
                            <cq:responsive
                                cq:lastRolledout="{Date}2024-02-08T16:34:13.801Z"
                                cq:lastRolledoutBy="msm-service"
                                jcr:mixinTypes="[cq:LiveRelationship]"
                                jcr:primaryType="nt:unstructured">
                                <default
                                    cq:lastRolledout="{Date}2024-02-08T16:34:13.858Z"
                                    cq:lastRolledoutBy="msm-service"
                                    jcr:mixinTypes="[cq:LiveRelationship]"
                                    jcr:primaryType="nt:unstructured"
                                    offset="2"
                                    width="4"/>
                                <phone
                                    cq:lastRolledout="{Date}2024-02-08T16:34:13.864Z"
                                    cq:lastRolledoutBy="msm-service"
                                    jcr:mixinTypes="[cq:LiveRelationship]"
                                    jcr:primaryType="nt:unstructured"
                                    offset="1"
                                    width="10"/>
                            </cq:responsive>
                        </image>
                        <spacer
                            cq:lastRolledout="{Date}2024-02-08T16:34:13.871Z"
                            cq:lastRolledoutBy="msm-service"
                            jcr:lastModified="{Date}2024-02-08T16:34:13.866Z"
                            jcr:lastModifiedBy="d.mariotti@adiacent.com"
                            jcr:mixinTypes="[cq:LiveRelationship]"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/spacer"
                            spacer="40"/>
                        <text
                            cq:lastRolledout="{Date}2024-02-08T16:34:13.878Z"
                            cq:lastRolledoutBy="msm-service"
                            jcr:lastModified="{Date}2024-02-08T16:34:13.873Z"
                            jcr:lastModifiedBy="Importer"
                            jcr:mixinTypes="[cq:LiveRelationship]"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/text"
                            text="&lt;p style=&quot;text-align: center;&quot;>&lt;span style=&quot;font-family: Arial;&quot;>&lt;strong>&lt;img alt=&quot;&quot; src=&quot;/Portals/31/images/news/Logo-DIAMOND-web.jpg&quot; style=&quot;text-align: center;&quot; />&lt;/strong>&lt;/span>&lt;/p>&#xa;&#xa;&lt;p>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p style=&quot;text-align: center;&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p style=&quot;text-align: center;&quot;>&lt;em>&lt;span style=&quot;font-family: Arial;&quot;>SEL24/MEN1703 is being Evaluated for the Treatment of Acute Myeloid Leukemia (AML)&lt;/span>&lt;/em>&lt;/p>&#xa;&#xa;&lt;p style=&quot;text-align: center;&quot;>&lt;em>&lt;span style=&quot;font-family: Arial;&quot;>Poster Accepted for Presentation at the 62&lt;sup>nd&lt;/sup> American Society of Hematology (ASH) Annual Meeting&lt;/span>&lt;/em>&lt;/p>&#xa;&#xa;&lt;p style=&quot;text-align: justify;&quot;>&lt;span style=&quot;font-family: Arial;&quot;>&lt;strong>&lt;span>Pomezia, Italy, December 1&lt;sup>st&lt;/sup>, 2020&lt;/span>&lt;/strong> &amp;ndash; &lt;span style=&quot;color: black;&quot;>Menarini Ricerche, the R&amp;amp;D division of the Menarini Group, reported today the positive results of the pharmacodynamic assay demonstrating target engagement in the dose escalation part of &lt;/span>the DIAMOND-01 trial (CLI24-001; clinicaltrials.gov identifier NCT03008187), a study investigating &lt;a href=&quot;https://www.menarini.com/Home/Innovation-Research/MEN1703&quot;>SEL24/MEN1703&lt;/a>, a first-in-class, orally available, dual PIM/FLT3 inhibitor as single agent in Acute Myeloid Leukemia (AML).&lt;/span>&lt;/p>&#xa;&#xa;&lt;p style=&quot;text-align: justify;&quot;>&lt;span style=&quot;font-family: Arial;&quot;>The poster entitled &lt;em>&amp;ldquo;SEL24/MEN1703 provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamic (PD) Assay in the Dose Escalation Part of First-in-Human DIAMOND Trial&amp;rdquo; &lt;/em>will be presented at the 62&lt;sup>nd&lt;/sup> American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place virtually on December 5-8. &lt;/span>&lt;/p>&#xa;&#xa;&lt;p style=&quot;text-align: justify;&quot;>&lt;span style=&quot;font-family: Arial;&quot;>&amp;ldquo;&lt;em>We are pleased with the preliminary, positive results observed with SEL24/MEN1703, a PIM/FLT3 inhibitor under investigation for the treatment of AML. As outlined in our ASH poster presentation, the dose escalation phase of the DIAMOND-01 trial showed that SEL24/MEN1703 has a manageable safety profile and results in a meaningful target engagement in peripheral blood and bone marrow blast cells from patients treated with SEL24/MEN1703&lt;/em>,&amp;rdquo; said Andrea Pellacani, General Manager of Menarini Ricerche. &amp;ldquo;&lt;em>We look forward to continuing our investigation of SEL24/MEN1703 as a potential new treatment for this aggressive and hard-to-treat cancer&lt;/em>&lt;em>&lt;span>, as part of our commitment to develop effective innovative therapies that can make a difference in the lives of cancer patients&lt;/span>&lt;/em>.&amp;rdquo;&lt;/span>&lt;/p>&#xa;&#xa;&lt;p style=&quot;text-align: justify;&quot;>&lt;span style=&quot;font-family: Arial;&quot;>DIAMOND-01 is the First-in-Human, Phase I/II dose escalation and cohort expansion trial of &lt;a href=&quot;https://www.menarini.com/Home/Innovation-Research/MEN1703&quot;>SEL24/MEN1703&lt;/a>, in-licensed by Menarini from Ryvu Therapeutics, in AML. The study has completed the dose escalation part showing a manageable safety profile up to the recommended dose of 125 mg/day, with initial evidence of anti-leukemic activity in a single agent setting. &lt;/span>&lt;/p>&#xa;&#xa;&lt;p style=&quot;text-align: justify;&quot;>&lt;span style=&quot;font-family: Arial;&quot;>The objective of the pharmacodynamic assessment was to investigate the degree of target engagement achieved at different doses of &lt;a href=&quot;https://www.menarini.com/Home/Innovation-Research/MEN1703&quot;>SEL24/MEN1703&lt;/a>, by measuring the phosphorylation of S6 (pS6), a downstream effector of the PIM/FLT3 signaling pathway. In addition, the correlation between pS6 levels and the anti-leukemic effect of &lt;a href=&quot;https://www.menarini.com/Home/Innovation-Research/MEN1703&quot;>SEL24/MEN1703&lt;/a> was assessed in samples collected from patients enrolled in the dose escalation part of the DIAMOND-01 trial. The quantitative assessment of pS6 at a single-cell level was performed both on peripheral blood (PB) and bone marrow (BM) blast cells samples.&lt;/span>&lt;/p>&#xa;&#xa;&lt;p style=&quot;text-align: justify;&quot;>&lt;span style=&quot;font-family: Arial;&quot;>The results of this assay confirmed that meaningful target engagement was achieved, both in PB and BM blast cells, in patients treated with &lt;a href=&quot;https://www.menarini.com/Home/Innovation-Research/MEN1703&quot;>SEL24/MEN1703&lt;/a> at 100 mg/day (one dose level below the recommended dose) and at 125 mg/day. Moreover, preliminary data suggest that the PIM/FLT3 pathway inhibition might be associated with blast count reduction, particularly in those patients showing high phosphorylation of S6 at baseline.&lt;/span>&lt;/p>&#xa;&#xa;&lt;p style=&quot;text-align: justify;&quot;>&lt;span style=&quot;font-family: Arial;&quot;>We will continue to measure target engagement with this assay in the cohort expansion part of the DIAMOND-01 trial, which is currently recruiting patients with relapsed or refractory AML in both the EU and the US.&lt;/span>&lt;/p>"
                            textIsRich="true"/>
                        <cq:responsive
                            cq:lastRolledout="{Date}2024-02-08T16:34:13.961Z"
                            cq:lastRolledoutBy="msm-service"
                            jcr:mixinTypes="[cq:LiveRelationship]"
                            jcr:primaryType="nt:unstructured">
                            <default
                                cq:lastRolledout="{Date}2024-02-08T16:34:14.036Z"
                                cq:lastRolledoutBy="msm-service"
                                jcr:mixinTypes="[cq:LiveRelationship]"
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="8"/>
                            <tablet
                                cq:lastRolledout="{Date}2024-02-08T16:34:14.042Z"
                                cq:lastRolledoutBy="msm-service"
                                jcr:mixinTypes="[cq:LiveRelationship]"
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="8"/>
                            <phone
                                cq:lastRolledout="{Date}2024-02-08T16:34:14.047Z"
                                cq:lastRolledoutBy="msm-service"
                                jcr:mixinTypes="[cq:LiveRelationship]"
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="12"/>
                        </cq:responsive>
                    </container>
                </container>
            </container>
        </root>
        <cq:featuredimage
            cq:lastRolledout="{Date}2024-02-08T16:34:14.053Z"
            cq:lastRolledoutBy="msm-service"
            jcr:mixinTypes="[cq:LiveRelationship]"
            jcr:primaryType="nt:unstructured"
            sling:resourceType="core/wcm/components/image/v3/image"
            altValueFromDAM="{Boolean}false"
            fileReference="/content/dam/menarini-berlinchemie/assets/news/img-diamond_thumbnail.jpg"/>
    </jcr:content>
</jcr:root>
